The financial toll of cancer: uncovering the links between financial toxicity and symptom burden
The Oncologist · 04.06.2025 · 30 (6)
DOI: 10.1093/oncolo/oyaf131 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift The Oncologist, online erschienen am 26.06.2025. Verfasst von Marco Filetti und 12 weiteren Autor:innen. Beteiligte Einrichtung: Phase 1 Unit, Fondazione Policlinico Universitario A. Gemelli, IRCCS, 00168 Rome, Italy. Hauptthemen laut MEDLINE: Cost of Illness, Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose
This prospective observational study investigated the relationship between financial toxicity, symptom burden, disease characteristics and out-of-pocket (OOP) medication use in patients with cancer across 5 Italian institutions.
Methods
A cross-sectional survey assessed financial toxicity, symptom burden and OOP costs sustained by patients with cancer using validated questionnaires (COST, PERSONS). Associations between financial toxicity (COST score), symptom burden (PERSONS score) and clinical variables were explored.
Results
Among 211 respondents, mean COST score was 23 (SD 9.1) and 128 (60%) scored < 26, indicating financial toxicity. Symptom burden measured by the PERSONS score was associated with a higher OOP medications use (r = 0.449, P < .001) and inversely related to financial toxicity (r = −0.431; P < .001). In our study population, median number of OOP drug was 2 (IQR 1-2), most commonly analgesics and laxatives. There was a significantly worse COST score among patients using OOP analgesic: 19.8 (SD 9.5) vs 25.6 (SD 7.9), P < .001 and laxatives: 19.2 (SD 8.2) vs 24.4 [(SD 9.1), P < .00]. Overall, OOP drugs were linked to higher symptom burden (P < .001) and financial toxicity (P < .001).
Conclusions
The severity of symptoms and their management with OOP medications was significantly associated with patients’ financial toxicity. These findings highlight the importance of integrating financial toxicity assessment into routine cancer care to optimize patient outcomes and well-being.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Phase 1 Unit, Fondazione Policlinico Universitario A. Gemelli, IRCCS, 00168 Rome, Italy.
- Division of Cancer, Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London W12 0HS, UK.
- Medical Oncology Unit B, Department of Radiology, Oncology and Pathology, Policlinico Umberto I, Sapienza University of Rome, 00161 Rome, Italy.
- Hospice Care Unit, USL Umbria 1, 06126 Perugia, Italy.
- Azienda Ospedaliera S. Maria S.C. Oncologia, 05100 Terni, Italy.
- Palliative Care Unit, Ospedale Sirai, Carbonia, ASSL 09013 Carbonia, Italy.
ORCID-Profile: Marco Filetti, Pasquale Lombardi, Raffaele Giusti
Zitieren
APA
Filetti, M., Lombardi, P., Gentile, G., Toccaceli, P., Fumi, G., Vacca, D., Colpani, E., Ravoni, G., Mazzuca, F., Daniele, G., Porzio, G., Bruera, E., & Giusti, R. (2025). The financial toll of cancer: uncovering the links between financial toxicity and symptom burden. The Oncologist, 30(6). https://doi.org/10.1093/oncolo/oyaf131
Vancouver
Filetti M, Lombardi P, Gentile G, Toccaceli P, Fumi G, Vacca D, et al. The financial toll of cancer: uncovering the links between financial toxicity and symptom burden. The Oncologist. 2025;30(6). doi:10.1093/oncolo/oyaf131
BibTeX
@article{Filetti2025,
author = {Filetti, Marco and Lombardi, Pasquale and Gentile, Gabriella and Toccaceli, Paolo and Fumi, Guglielmo and Vacca, Denise and Colpani, Emilia and Ravoni, Giulio and Mazzuca, Federica and Daniele, Gennaro and Porzio, Giampiero and Bruera, Eduardo and Giusti, Raffaele},
title = {The financial toll of cancer: uncovering the links between financial toxicity and symptom burden},
journal = {The Oncologist},
year = {2025},
volume = {30},
number = {6},
doi = {10.1093/oncolo/oyaf131}
}
EUVIMED